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Abstract
Background
Growth differentiation factor-15 (GDF-15), Cystatin C and C-reactive protein (CRP) have
been discussed as biomarkers for prediction of cardiac diseases. The aim of this study was
to investigate the predictive value of single and repeated measurements of GDF-15 com-
pared to Cystatin C and CRP for incidence of heart failure (HF) and death due to coronary
heart disease (CHD) in the general population.
Methods and results
Levels of GDF-15, CRP and Cystatin C were determined in three repeated measurements
collected 5 years apart in the DAN-MONICA (Danish-Multinational MONitoring of trends
and determinants in Cardiovascular disease) cohort (participants at baseline n = 3785). Cox
regression models adjusted for cardiovascular risk factors revealed significantly increased
hazard ratios (HR) for GDF-15 for incident HF 1.36 (HR per interquartile range (IQR)
increase, 95% confidence interval (CI): 1.16; 1.59) and for death from CHD 1.51 (HR per
IQR increase, 95% CI: 1.31, 1.75) (both with p<0.001). Joint modeling of time-to-event and
longitudinal GDF-15 over a median 27-year follow-up period showed that the marker evolu-
tion was positively associated with death of CHD (HR per IQR increase 3.02 95% CI: (2.26,
4.04), p < 0.001) and HF (HR per IQR increase 2.12 95% CI: (1.54, 2.92), p<0.001). How-
ever using Cox models with follow-up time starting at the time of the third examination, serial
measurement of GDF-15, modeled as changes between the measurements, did not
improve prediction over that of the most recent measurement.
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Conclusions
GDF-15 is a promising biomarker for prediction of HF and death due to CHD in the general
population, which may provide prognostic information to already established clinical bio-
markers. Repeated measurements of GDF-15 displayed only a slight improvement in the
prediction of these endpoints compared to a single measurement.
Introduction
The prevalence of heart failure (HF) is steadily increasing with the growing elderly population
with a current prevalence of over 23 million worldwide [1]. Simultaneously, cardiovascular
diseases (CVD) remain the number one cause of death in Europe although the incidence of
coronary heart disease (CHD) has declined [2]. The use of circulating biomarkers has
improved risk estimation of HF and CVD in apparently healthy individuals [3, 4]. The N-ter-
minal pro-B-type natriuretic peptide (NT-proBNP), which is released due to myocardial stress
and cardiac volume overload, has become one of the most important biomarkers in diagnosis
and prognosis of HF [4]. With the advent of novel biomarkers and their combinations, the
prognostic value and their effect in the primary prevention in patients suffering from CVD or
HF are currently discussed. Growth differentiation factor-15 (GDF-15), also known as macro-
phage inhibitory cytokine-1 (MIC-1), is a member of the transforming growth factor (TGF-ß)
cytokine superfamily, which has been examined as a novel emerging biomarker in HF, cancer
and atherosclerotic diseases including CVD [5–10]. Cardiac expression of GDF-15 has been
induced in response to oxidative stress, ischemia/reperfusion injury, inflammation, stress
induced by biomechanically stretching in the heart and pressure overload [11–13]. Nonethe-
less, in community-based populations, Brown and colleagues first described in a prospective
case-control study that increased plasma levels of GDF-15 in healthy women were accompa-
nied with a higher risk for future cardiovascular events [14]. In addition, several subsequent
studies revealed that increased levels of GDF-15 are associated with increased cardiovascular
mortality and all-cause mortality independent of classical cardiovascular risk factors in com-
munity-dwelling individuals [8, 15–17]. In 2012 the Framingham Heart Study first showed
that GDF-15 is strongly related with the risk of HF and death in a community based setting
with 3,428 participants [18].
The aim of the present study was to investigate the prognostic value of a single measure-
ment of GDF-15 for prediction of the development of HF and death due to coronary heart dis-
ease (CHD) in the general population. Moreover, we examined whether long-term changes
(repeated measurements) of GDF-15, could provide additional prognostic information in this
study population. For that purpose, comprehensive data of the DAN-MONICA Cohort (Dan-
ish-Multinational MONitoring of trends and determinants in Cardiovascular disease) was
analyzed with a median follow-up of 27 years of more than 3500 individuals.
Methods
Study population
The present study included the DAN-MONICA I cohort, using data from the BiomaCaRE
(Biomarker for Cardiovascular Risk Assessment in Europe) project [19]. This prospective pop-
ulation-based cohort is derived as a random sample of the population in eleven municipalities
in Copenhagen County, Denmark [20]. Random sampling is based on the national population
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register, stratified by gender and year of birth. The cohort was linked to the National Hospital
Discharge Register, to the Causes of Death Register and the Civil Registration System using the
unique personal identification number in Denmark. All participants gave informed consent.
The cohort consists of men and women aged 30–60 years having two repeated measurements
of baseline risk factors. Round 1 of this cohort constitutes the baseline examinations carried
out in 1982–84 (n = 3785). Participants were re-examined in 1987–1988 (Round 2, n = 2987)
and 1993–1994 (Round 3, n = 2656). The cohort was followed up until December 2009 using
linkage to the National Cause of Death Register and National Hospital Discharge Register. A
hospitalization or death with ICD-8 code 427.0, 427.1 or 428, or ICD-10 code I11.0, I13.0,
I13.2 or I50 was considered to indicate heart failure. The cause of death due to CHD was
coded by ICD-8 code 410–414 or ICD-10 code I20-25. The study was approved by the local
ethics committee in Copenhagen County (Københavns Amt, Den videnskabsetiske komite;
No: 1980-272-2 1051 NE7bt 2-16-2/43 (85) KA 90238).
The endpoints were defined as first diagnosis of HF and death due to CHD.
Laboratory methods
Plasma and serum samples were separated from venous blood and stored at -20˚C in Glostrup
from 1986/1987 and since 2010 in the MORGAM/BiomarCaRE laboratory (Hamburg) at
-80˚C. All biomarkers were measured in the MORGAM/BiomarCaRE laboratory. GDF-15
(pg/mL) was measured in serum using the Abbott ARCHITECT GDF-15 assay with measure-
ment range between 0–5000 pg/ml and a lower limit of detection (LOD) of 5 pg/. The inter-
assay coefficient of variation (CV) was 4.68%, the intra-assay CV was 2.20% mL assessed at a
GDF-15 level of 500 pg/mL. Creatinine (mg/dl) was measured using the Abbott ARCHITECT
Creatinine enzymatic assay. Estimated glomerular filtration rate (eGFR) was computed using
the creatinine based CKD-EPI formula. CRP was measured using the Abbott ARCHITECT
CRP vario assay with the measurement ranges of 0.01–16 mg/dl and a LOD of 0.01 mg/dL.
The CV was determined at 0.5 mg/dl. The inter-assay had a CV of 4.71%, the intra-assay CV of
0.50%. Cystatin C was measured using the Abbott Cystatin C ARCHITECT c8000 assay with
measurement ranges 0.05–8.33 mg/L and a LOD of 0.05 mg/l. The inter-assay and intra-assay
CV was 3.97% and 1.27% assessed at a Cystatin C level of 0.71 mg/L, respectively.
Statistical analysis
Baseline characteristics are given as absolute and relative frequencies for categorical variables,
mean and standard deviation or quartiles for continuous variables.
Multiple imputation was used to deal with missing data. Twenty imputed datasets were pro-
duced using chained equations [21]. Predictive mean matching was used for all variables and
time-to-event information was incorporated into the imputation model. Separate imputations
were produced for men and women.
First, the association of the first measurements (round 1) of the biomarkers of interest
(GDF-15, CRP and Cystatin C) with death due to CHD and incident HF was examined. The
biomarkers were categorized using their quartiles and survival curves were produced by the
Kaplan-Meier method. The logrank test was performed to compare the survival curves defined
by the biomarker fourths. Afterwards, Cox regressions adjusted for sex, overweight (BMI> 25
kg/m2), systolic blood pressure, diabetes, daily smoker, renal insufficiency (eGFR< 60 mL/
min for 1.73m2) were computed. Age was used as the time scale in the Cox models. To quantify
the discrimination of the 25-year event probabilities derived from these Cox models the C-
index was computed. To obtain these probabilities the Breslow estimator of the baseline sur-
vival function was used. 10-fold cross-validation was used to avoid over-optimism resulting
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from assessment of the model performance on the same data in which the model was derived
[22].
To examine the association of outcome to the longitudinal measurements of the biomark-
ers, a joint model for the longitudinal marker and time to event was computed [23, 24]. The
joint model consists of two parts, a linear mixed effect model for the biomarker and a propor-
tional hazards model for the survival part. For each marker, the linear mixed effect model
included a random intercept and a random slope from time since baseline for each individual.
Sex, age at round 1 (cross-sectional effect of age), time since baseline (longitudinal effect of
age), overweight, systolic blood pressure, LDL cholesterol, diabetes, daily smoker and renal
insufficiency were used as fixed effects in the mixed effect model. The survival part of the joint
model used age as the time scale and was adjusted for the same covariates as was the Cox
model described in the previous paragraph. For the latter model the values of the covariates
were updated at each round.
To assess how changes in biomarker values may improve predictive performance over that
of the most recent measurement, the available marker history up to the third examination
(round 3) was modelled in different ways. The difference between the values at round 3 and
round 2 (round 1 respectively) was considered and the round 3 measurement was also used.
These variables entered a Cox model with follow-up time starting at round 3. All models used
the same adjusted covariates as the Cox regressions described earlier and age was used as the
time scale. The models including the marker differences as predictors where further adjusted
for the round 3 measurement of the corresponding marker. The C-index was calculated to
examine the discrimination of the marker trend over the last available marker measurement
(at round 3).
For all regression analyses the biomarkers were used after being log-transformed and their
hazard ratios are presented per interquartile range (IQR) increase, where the IQR is defined as
the distance between the 25th and 75th percentile of the log-transformed marker. Analyses were
performed with R version 3.3.0 [25]. A more detailed description is provided in the S1 File.
Results
Baseline characteristics
The baseline characteristics of the imputed datasets of the patients for each round are shown
in Table 1. Baseline characteristics of the nonimputed dataset are shown in S1 Table.
The mean age on examination was 45.5 (standard deviation: 11.0 years (51.3% male). The
median follow-up was 27.51 years for death from CHD und 27.42 years for HF. Median GDF-
15 serum levels at baseline were 454.9 pg/ml (25th percentile: 341.8 pg/ml; 75th percentile:
625.1 pg/ml).
Association of single baseline measurements of GDF-15, Cystatin C and
CRP with death from CHD or incidence of HF
Kaplan-Meier curves (Fig 1) reflect the difference in event-free survival for the endpoints
death from CHD or incidence of HF according to the quartiles of GDF-15, CRP and Cystatin
C. Kaplan-Meier curves showed increasing event rates for both endpoints with increasing
GDF-15 levels for a median follow-up period of 27.53 years. These Kaplan-Meier curves indi-
cated a higher risk of death from CHD or incidence of HF with higher GDF-15 levels.
Cox regression models revealed significantly increased hazard ratios (HR) for GDF-15 for
incident HF (1.36 per IQR increase, 95% confidence interval (CI): 1.16; 1.59) and death from
CHD (1.51 per IQR increase, 95% CI: 1.31, 1.75) (both with p-value <0.001) (Fig 2).
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Table 1. Baseline characteristics of the DAN-MONICA cohort according to round 1–3 (Data for the imputed datasets).
round 1
(n = 3785)
round 2
(n = 3672)
round 3
(n = 3461)
Examination age (years) 45.5±11.0 50.2±11.0 55.6±10.9
Male (%) 1940.0 (51.3) 1867.0 (50.8) 1726.0 (49.9)
BMI (kg/m2) 24.6±3.9 25.2±4.0 26.0±4.3
BMI>25 kg/m2 (%) 1524.0 (40.3) 1696.4 (46.2) 1867.8 (54.0)
HDL cholesterol (mmol/L) 1.5±0.4 1.5±0.4 1.4±0.4
LDL cholesterol (mmol/L) 3.7±1.1 4.1±1.1 4.1±1.1
Total cholesterol (mmol/L) 5.8±1.2 6.1±1.2 6.2±1.2
Systolic BP (mmHg) 123.3±16.8 126.6±19.1 130.0±19.6
Diastolic BP (mmHg) 77.2±10.9 81.8±10.6 82.3±10.8
Daily smoker (%) 1768.0 (46.7) 1824.8 (49.7) 1362.5 (39.4)
Diabetes No. (%) 86.0 (2.3) 122.9 (3.3) 153.9 (4.4)
eGFR (mL/min for 1.73m2) 109.4 (96.8, 119.9) 104.1 (92.5, 113.5) 97.3 (85.3, 107.1)
eGFR<60 mL/min for 1.73m2 No. (%) 78.5 (2.1) 70.0 (1.9) 111.7 (3.2)
Creatinine (mg/dL) 0.8 (0.7, 0.9) 0.8 (0.7, 0.9) 0.8 (0.7, 1.0)
Cystatin C (mg/L) 0.7 (0.6, 0.8) 0.7 (0.7, 0.8) 0.8 (0.7, 0.9)
CRP (mg/L) 1.2 (0.6, 2.8) 1.2 (0.6, 2.8) 1.5 (0.7, 3.6)
GDF-15 (pg/mL) 454.9 (341.8, 625.1) 487.4 (368.5, 653.6) 565.8 (425.3, 765.2)
Baseline characteristics are given as absolute and relative frequencies for categorical variables, mean ± standard deviation or quartiles (median [25th percentile, 75th
percentile]) for continuous variables. The baseline survey was carried in 1982–84 (round 1). The cohort was re-examined in1987-1988 (round 2) and 1993–1994 (round
3). BMI = body mass index, HDL = high-density lipoprotein, LDL = low-density lipoprotein, BP = blood pressure, eGFR = estimated glomerular infiltration rate,
CRP = C-reactive protein, GDF-15 = Growth differentiation factor-15.
Number of individuals after multiple imputation
https://doi.org/10.1371/journal.pone.0197497.t001
Fig 1. Survival curves for the endpoints death from CHD and incidence of HF. Survival curves for the endpoints
death from CHD and incidence of HF according to the biomarker quarters. The p-value shown is for the logrank test.
https://doi.org/10.1371/journal.pone.0197497.g001
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Comparison of prediction models based on the Cox regression with C-
statistics
To assess the discriminative strength of the prediction models, C-indices were calculated
(Table 2). Comparing the C-indices of the models with the biomarker GDF-15 to the base
models for HF 0.819 (95% CI: 0.788; 0.850) and for death from CHD 0.838 (95% CI: 0.807;
0.869), the p-value for death from CHD was significant (p = 0.0097). For comparison, we fitted
models with CRP and Cystatin C. The predictive value was significant only for GDF-15
according to death from CHD, while CRP was predictive for HF. C-index improvements for
each biomarker alone was modest. The C-indices for the models including all three biomarkers
Fig 2. Biomarker hazard ratios for the endpoints death from CHD and incidence of HF. Cox models were adjusted
for age (as the time scale), sex, overweight (BMI> 25 kg/m2), systolic blood pressure, diabetes, daily smoker, renal
insufficiency (eGFR> 60 ml/min or 1,73m3). The biomarkers were used after being log-transformed. The follow-up
time begins at round 1. Only round 1 measurements are used. IQR: interquartile range.
https://doi.org/10.1371/journal.pone.0197497.g002
Table 2. C-indices for 25-year prediction of death from CHD and HF.
Death from CHD C-index (95% CI) C-index differences (95% CI) p-value
Base model 0.832 (0.802, 0.863) - -
GDF-15 model 0.838 (0.807, 0.869) 0.00582 (0.00141, 0.01022) 0.0097
CRP model 0.834 (0.803, 0.865) 0.00166 (-0.00161, 0.00492) 0.32
CYSTATIN C model 0.836 (0.805, 0.867) 0.00371 (-0.00058, 0.00800) 0.090
GDF-15 + CRP + CYSTATIN C model 0.839 (0.808, 0.870) 0.00691 (0.00160, 0.01222) 0.011
HF
Base model 0.817 (0.786, 0.847) - -
GDF-15 model 0.819 (0.788, 0.850) 0.00256 (-0.00073, 0.00584) 0.13
CRP model 0.824 (0.794, 0.855) 0.00780 (0.00254, 0.01306) 0.0037
CYSTATIN C model 0.816 (0.786, 0.847) 0.00018 (-0.00382, 0.00345) 0.92
GDF-15 + CRP + CYSTATIN C model 0.824 (0.793, 0.855) 0.00719 (0.00126, 0.01313) 0.018
The 25-year predicted probabilities are based on Cox models. The base model is based on the following predictors:
age, sex, overweight (BMI > 25 kg/m2), systolic blood pressure, diabetes, daily smoker, renal insufficiency
(eGFR > 60 ml/min or 1.73m3). The biomarkers are added to the base model. The follow-up time begins at round 1.
Only round 1 measurements are used.
https://doi.org/10.1371/journal.pone.0197497.t002
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(GDF-15, CRP and Cystatin C) to predict HF (0.824; 95% CI: 0.793, 0.855, p = 0.018) and
death from CHD (0.839; 95% 0.808, 0.870, p = 0.011) were significant.
Serial measurement vs. single measurement of GDF-15: Evaluation of
repeated measurements using deltas and joint modeling
To evaluate if serial measurement of GDF-15 may be more useful than the most recent mea-
surement of GDF-15, the change from round 2 (round 1 respectively) to round 3 was calcu-
lated. For GDF-15 no association could be shown with time to event (death from CHD, HF)
for the changes on top of the information provided by the most recent measurement (Table 3).
The CRP changes from round 1 to round 3 were associated with HF and the Cystatin C
changes from round 2 to round 3 with death from CHD (both on top of the last marker mea-
surement). The results for CRP and Cystatin C can be found in Table 3. The changes did not
Table 3. Hazard ratios for Cox models with follow-up starting at round 3.
Death from CHD
GDF-15 HR per IQR increase (95% CI) p-value
round 3 1.99 (1.57, 2.53) <0.001
delta round 3—round 1 1.01 (0.85, 1.2) 0.93
delta round 3—round 2 1.03 (0.83, 1.29) 0.76
CRP
round 3 1.66 (1.31, 2.12) <0.001
delta round 3—round 1 0.95 (0.77, 1.16) 0.61
delta round 3—round 2 0.93 (0.73, 1.19) 0.58
Cystatin C
round 3 1.5 (1.23, 1.83) <0.001
delta round 3—round 1 0.91 (0.79, 1.05) 0.18
delta round 3—round 2 1.25 (1.1, 1.43) <0.001
HF
GDF-15
round 3 1.74 (1.38, 2.29 <0.001
delta round 3—round 1 1.16 (0.99, 1.36) 0.066
delta round 3—round 2 1.21 (0.97, 1.5) 0.085
CRP
round 3 1.43 (1.14, 1.8) 0.0023
delta round 3—round 1 0.83 (0.69, 0.99) 0.043
delta round 3—round 2 0.85 (0.7, 1.05) 0.13
Cystatin C
round 3 1.1 (0.89, 1.36) 0.37
delta round 3—round 1 1.06 (0.93, 1.2) 0.40
delta round 3—round 2 1.09 (0.91, 1.29) 0.35
Hazard ratios are presented for the round 3 measurement of GDF-15, CRP and Cystatin C and for the differences
(delta) between rounds 3 and 1 and round 3 and 2. GDF-15, CRP and Cystatin C included used after log-
transformation. The models adjusted for age, sex, overweight (BMI > 25 kg/m2), systolic blood pressure, diabetes,
daily smoker and renal insufficiency (eGFR > 60 ml/min or 1.73m3). The models including a delta are additionally
adjusted for the corresponding marker round 3 measurement. By “delta round 3 –round i”, i = 1 or 2, it is meant the
(absolute) difference of the marker values at rounds 3 and i, that is, marker value at round 3 minus marker value at
round i.
https://doi.org/10.1371/journal.pone.0197497.t003
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improve the C-index of the model with the most recent measurement for any of the markers
(results not shown).
Joint modeling was used to evaluate the association of the longitudinal history of GDF-15
on the endpoints death to CHD or incident of HF (Table 4 and Table 5). This approach
attempts to capture the underlying longitudinal development of the marker free of measure-
ment error and estimates the association of the error-free marker with time-to-event [23]. The
longitudinal measurements of GDF-15 were positively associated with death of CHD (HR per
IQR 3.02 95% CI: (2.26, 4.04), p< 0.001) and HF (HR per IQR 2.12 95% CI: (1.54, 2.92),
p< 0.001). Cystatin C and CRP showed also a positive association but smaller HRs for CHD
but without a significant association for Cystatin and HF (Tables 4 and 5).
Discussion
The present study revealed that a single measurement of GDF-15, independent of classical car-
diovascular risk factors, seems to enhance risk prediction of death from CHD and HF com-
pared to the biomarkers CRP and Cystatin C in the general population of the DAN-MONICA
cohort. In the joint modeling of the longitudinal measurements of the biomarkers and the
study endpoints, there was a stronger positive association between GDF-15 and the hazards of
CHD death and HF than for single biomarker measurements. However, using GDF-15 differ-
ences of the most recent measurement with previous measurements no association could be
shown and no significant improvement in discrimination was observed over that provided by
the last measurement. In summary, in our study GDF-15 measurements over the time only
slightly improved risk prediction for the development of HF and death due to CHD.
In the general population, the Women´s Health Study in 2002, a prospective, nested, case-
control study, was the first study which revealed that increased plasma levels of GDF-15 were
Table 4. Longitudinal biomarker measurements: Hazard ratios for death from CHD estimated by joint models.
HR per IQR (95% CI) p-value
GDF-15 3.02 (2.26, 4.04) <0.001
CRP 2.69 (1.88, 3.84) <0.001
Cystatin C 1.59 (1.3, 1.93) <0.001
The interquartile range (IQR) of the round 1 biomarker measurement is used. Biomarkers are used after log-
transformation. The hazard ratio is derived from the proportional hazards model part of the joint model and it
measures the association of the time-course of the corresponding biomarker with time to death from CHD. The
proportional hazards model part of the joint model was adjusted for age, sex, overweight (BMI > 25 kg/m2), systolic
blood pressure, diabetes, daily smoker and renal insufficiency (eGFR > 60 ml/min or 1.73m3).
https://doi.org/10.1371/journal.pone.0197497.t004
Table 5. Longitudinal biomarker measurements: Hazard ratios for incident HF estimated by joint models.
HR per IQR (95% CI) p-value
GDF-15 2.12 (1.54, 2.92) <0.001
CRP 2.27 (1.64, 3.15) <0.001
Cystatin C 1.14 (0.91,1.45) 0.25
The interquartile range (IQR) of the round 1 biomarker measurement is used. Biomarkers are used after log-
transformation. The hazard ratio is derived from the proportional hazards model part of the joint model and it
measures the association of the time-course of the corresponding biomarker with time to HF. The proportional
hazards model part of the joint model was adjusted for age, sex, overweight (BMI > 25 kg/m2), systolic blood
pressure, diabetes, daily smoker and renal insufficiency (eGFR > 60 ml/min or 1.73m3).
https://doi.org/10.1371/journal.pone.0197497.t005
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associated with a higher risk of CVD events in healthy women [14]. In detail, the risk of future
CVD events remained after adjustment for established cardiovascular risk factors and was addi-
tive to CRP as an inflammatory biomarker [14]. Further clinical studies observed that GDF-15
was independently associated with increased cardiovascular mortality [15, 16]. In the Rancho
Bernardo Study, a study with almost only middle to upper class Caucasians, elevated plasma lev-
els of GDF-15 were powerful predictors of all-cause mortality and cardiovascular and non-car-
diovascular mortality and provided prognostic information beyond proBNP and CRP [15].
Accordingly, but in a younger multiethnic cohort with 3,291 participants, Rohatgi and col-
leagues showed in multivariable models adjusted for conventional risk factors that increased
GDF-15 concentrations ( 1,800 ng/L) were associated with cardiovascular mortality (HR 2.5;
95% CI 1.1–5.8, p = 0.03). Similar to the Rancho Bernardo Study these findings remained after
adjustment for CRP, troponin T and NT-proBNP [15, 16]. In line with these findings, our
results confirmed that single measurement of GDF-15 seems to be an independent predictor for
death due to CHD among subjects from the general population. Furthermore, we showed that
the measurement of GDF-15 did improve risk assessment for developing HF. Consistent to our
findings, the Framingham Heart study first revealed strong association of GDF-15 levels and an
increased risk for the development of HF [18]. Interestingly, in this community-dwelling cohort
with 3,428 participants GDF-15 as well as the other biomarkers soluble ST2 (sST2) and high-
sensitivity troponin I (hsTnI) did not predict coronary artery disease events, but total mortality
[18]. Notable, in some of the previous described community-dwelling cohorts participants were
elderly individuals with a higher-risk of developing CVD events and HF [15, 17, 26]. In compar-
ison, the Dan-MONICA cohort represents a middle-aged cohort which is more similar to the
Dallas Heart Study [16]. In contrast to our study population, which merely represents a north-
ern European cohort at that time, the strength of the Dallas Heart Study is the representation of
different ethnic backgrounds as mentioned above [16, 20].
Our results elucidated that repeated measurements of GDF-15, using the differences
between the biomarkers according to the measurements rounds, did not significantly improve
prediction of death from CHD or development of HF compared to single measurement. To
further evaluate the association of multiple measurements of GDF-15 over a 27-year period
with the end-points death to CHD or incidence of HF, we performed joint modeling for the
biomarkers GDF-15, Cystatin C and CRP in the DAN-MONICA cohort. In our analyses, we
chose to use joint models instead of the more widely used Cox regression with time dependent
covariates, because the latter may underestimate the magnitude of the association of the evolu-
tion in time of the biomarker and time-to-event [23, 24, 27]. The longitudinal evolution of the
biomarkers via joint modeling showed a stronger positive association of GDF-15 with death
from CHD and HF than the single biomarker measurements. Related to our findings, Eggers
et al. found that baseline concentrations of GDF-15 could predict future CVD events and espe-
cially all-cause mortality in an elderly community-dwelling population [26]. In detail, changes
over the time of GDF-15 predicted individual´s all-cause mortality, whereas GDF-15 and car-
diovascular events displayed no significant association [26].
In population-based studies, CRP as a marker for inflammation and Cystatin C as marker
for renal dysfunction have also been described to be associated with risk of future CVD [3, 28–
33]. Shlipak and colleagues first reported that Cystatin C was an independent predictor of
death from cardiovascular causes and superior to creatinine in an elderly population of the
community [29]. Numerous follow-up studies confirmed the role of Cystatin C as a predictor
of cardiovascular death in the general population [28, 30, 34]. Our data agree with these find-
ings, that Cystatin C is a strong predictor of cardiovascular death. Nonetheless, Cystatin C, in
our cohort has no prognostic value for future HF. Previous studies have noted the association
of CRP with cardiovascular mortality and development of HF in community-dwelling
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individuals [31–33, 35]. Our results also confirm other studies supporting that CRP is an inde-
pendent predictor for cardiovascular mortality in community-dwelling individuals. Moreover,
Zethelius et al. observed in a community-based elderly population that the addition of several
biomarkers (Troponin I, NT-proBNP, Cystatin C and high-sensitivity CRP) to traditional car-
diovascular risk factors improved risk stratification for cardiovascular death [36]. In this con-
text, our data also indicate that an including CRP measurement, and especially GDF-15
measurement, improves risk estimation of HF and death from CHD over that of cardiovascu-
lar risk factors.
Limitations and strengths
This study has several limitations and strengths. One major strength of the The DAN-MO-
NICA project is a large-scale and population-based cohort with more than 3,500 persons. In
addition, the long-term follow-up period of more than 27 years allows a reliable longitudinal
analysis. Nevertheless, this northern European cohort does not reveal possible ethnic differ-
ences in the results, which might withhold an immediate transfer into other populations.
Unfortunately, data on NT-proBNP are not available in the DAN-MONICA cohort, therefore
a comparison to NT-proBNP as a standard biomarker for HF risk stratification is not available.
In addition, we cannot exclude the possibility that storage at -20˚C the early years and, at
-80˚C since 2010 might have affected the measured biomarker levels as a result of potential
sample degradation or evaporation of water.
Conclusion
GDF-15 seems to be a promising biomarker for prediction of HF and death due to CHD in the
general population, which may enhance prognostic information to established clinical bio-
markers. Repeated measurements of GDF-15 displayed only a slight improvement in risk pre-
diction of these endpoints compared to single measurement. Prospective and randomized
clinical studies are needed to evaluate the utilization of GDF-15 in combination or comparison
to other biomarkers in the clinical setting.
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